# Fulgent Genetics, Inc.

Fulgent Genetics, Inc. is a public company listed on Nasdaq as FLGT, headquartered in El Monte, CA, United States.

## Company overview

- **Legal name:** Fulgent Genetics, Inc.
- **Former names in filing history:** Fulgent Diagnostics, Inc. (2016-06-09 to 2016-07-15)
- **Classification:** Public company
- **Industry (SIC):** 8071 — Services-Medical Laboratories
- **Headquarters:** El Monte, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: FLGT
- **SEC CIK:** 0001674930

## About

Fulgent Genetics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001674930, and its reported industry is Services-Medical Laboratories. In 10-K filed on 2026-02-27, it reported annual revenue of USD 322,671,000; net income of USD -60,513,000; total assets of USD 1,213,525,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $322.7M (USD 322,671,000)
- **Net income:** -$60.5M (USD -60,513,000)
- **Total assets:** $1.2B (USD 1,213,525,000)
- **Cash and equivalents:** $50.2M (USD 50,193,000)
- **Operating cash flow:** -$101.6M (USD -101,638,000)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $283.5M (USD 283,470,000)
- **Net income:** -$42.7M (USD -42,708,000)
- **Total assets:** $1.2B (USD 1,219,964,000)
- **Cash and equivalents:** $55.1M (USD 55,144,000)
- **Operating cash flow:** $21.1M (USD 21,060,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $289.2M (USD 289,213,000)
- **Net income:** -$167.8M (USD -167,825,000)
- **Total assets:** $1.2B (USD 1,235,328,000)
- **Cash and equivalents:** $97.5M (USD 97,473,000)
- **Operating cash flow:** $27.0M (USD 27,003,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $619.0M (USD 618,968,000)
- **Net income:** $143.4M (USD 143,403,000)
- **Total assets:** $1.4B (USD 1,386,053,000)
- **Cash and equivalents:** $79.5M (USD 79,506,000)
- **Operating cash flow:** $253.5M (USD 253,520,000)

## Recent SEC filings

- Form 10-Q — filed 2026-07-30 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-07-30 — period 2026-07-30 — 8-K
- Form 8-K — filed 2026-06-02 — period 2026-06-01 — 8-K
- Form 8-K — filed 2026-05-21 — period 2026-05-21 — 8-K
- Form 8-K — filed 2026-05-14 — period 2026-05-14 — 8-K
- Form 10-Q — filed 2026-05-01 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-01 — period 2026-05-01 — 8-K
- Form DEF 14A — filed 2026-03-31 — period 2026-03-31 — DEF 14A
- Form 8-K — filed 2026-03-17 — period 2026-03-17 — 8-K
- Form 10-K — filed 2026-02-27 — period 2025-12-31 — 10-K
- Form 8-K — filed 2026-02-27 — period 2026-02-27 — 8-K
- Form 8-K — filed 2025-12-22 — period 2025-12-20 — 8-K

---

Updated: 2026-10-23T05:02:54.863002+00:00

Canonical page: https://altss.com/profile/fulgent-genetics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology